WO2002054079A3 - Proteins, genes and their use for diagnosis and treatment of cardiac response - Google Patents

Proteins, genes and their use for diagnosis and treatment of cardiac response Download PDF

Info

Publication number
WO2002054079A3
WO2002054079A3 PCT/GB2001/005763 GB0105763W WO02054079A3 WO 2002054079 A3 WO2002054079 A3 WO 2002054079A3 GB 0105763 W GB0105763 W GB 0105763W WO 02054079 A3 WO02054079 A3 WO 02054079A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiac response
diagnosis
treatment
crpis
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/005763
Other languages
French (fr)
Other versions
WO2002054079A2 (en
Inventor
Eugene H Herman
Gordon Duane Holt
Frank D Sistare
Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
US Department of Health and Human Services
Government of the United States of America
Original Assignee
Oxford Glycosciences UK Ltd
US Department of Health and Human Services
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd, US Department of Health and Human Services, Government of the United States of America filed Critical Oxford Glycosciences UK Ltd
Priority to EP01272724A priority Critical patent/EP1356283A2/en
Priority to AU2002222307A priority patent/AU2002222307A1/en
Publication of WO2002054079A2 publication Critical patent/WO2002054079A2/en
Anticipated expiration legal-status Critical
Publication of WO2002054079A3 publication Critical patent/WO2002054079A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods and compositions for screening, diagnosis and prognosis of Cardiac Response, for monitoring the effectiveness of Cardiac Response treatment and for drug development. Cardiac Response-Associated Features (CRFs) detectable by two-dimensional electrophoresis of blood are described. The invention further provides Cardiac Response-Associated Protein Isoforms (CRPIs) detectable in biological sample preparations comprising isolated CRPIs, antibodies specific for CRPIs and kits comprising the aforesaid.
PCT/GB2001/005763 2000-10-24 2001-12-24 Proteins, genes and their use for diagnosis and treatment of cardiac response Ceased WO2002054079A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01272724A EP1356283A2 (en) 2000-10-24 2001-12-24 Proteins, genes and their use for diagnosis and treatment of cardiac response
AU2002222307A AU2002222307A1 (en) 2000-12-29 2001-12-24 Proteins, genes and their use for diagnosis and treatment of cardiac response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25497800P 2000-10-24 2000-10-24
US26038900P 2000-12-29 2000-12-29
US60/260,389 2000-12-29
US60/254,978 2001-10-24

Publications (2)

Publication Number Publication Date
WO2002054079A2 WO2002054079A2 (en) 2002-07-11
WO2002054079A3 true WO2002054079A3 (en) 2003-08-14

Family

ID=28044613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/005763 Ceased WO2002054079A2 (en) 2000-10-24 2001-12-24 Proteins, genes and their use for diagnosis and treatment of cardiac response

Country Status (2)

Country Link
EP (1) EP1356283A2 (en)
WO (1) WO2002054079A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047925A2 (en) * 1998-03-13 1999-09-23 Oxford Glycosciences (Uk) Ltd. Methods and compositions for diagnosis of rheumatoid arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047925A2 (en) * 1998-03-13 1999-09-23 Oxford Glycosciences (Uk) Ltd. Methods and compositions for diagnosis of rheumatoid arthritis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BOOTH D R ET AL: "A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family.", CIRCULATION. UNITED STATES 15 FEB 1995, vol. 91, no. 4, 15 February 1995 (1995-02-15), pages 962 - 967, XP002224261, ISSN: 0009-7322 *
BRITISH HEART JOURNAL. ENGLAND AUG 1993, vol. 70, no. 2, August 1993 (1993-08-01), pages 111 - 115, ISSN: 0007-0769 *
DATABASE MEDLINE [online] August 1993 (1993-08-01), HESSE A ET AL: "Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant.", XP002224264, Database accession no. NLM8038017 *
LABUGGER RALF ET AL: "Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction.", CIRCULATION, vol. 102, no. 11, 12 September 2000 (2000-09-12), pages 1221 - 1226, XP001080442, ISSN: 0009-7322 *
LI XIN PING ET AL: "A two-dimensional electrophoresis database of rat heart proteins.", ELECTROPHORESIS, vol. 20, no. 4-5, April 1999 (1999-04-01), pages 891 - 897, XP002224262, ISSN: 0173-0835 *
MANABE T ET AL: "A NONDENATURING PROTEIN MAP OF HUMAN PLASMA PROTEINS CORRELATED WITH A DENATURING POLYPEPTIDE MAP COMBINING TECHNIQUES OF MICRO TWO-DIMENSIONAL GEL ELECTROPHORESIS", ELECTROPHORESIS, WEINHEIM, DE, vol. 20, no. 4/5, April 1999 (1999-04-01), pages 830 - 835, XP001070186, ISSN: 0173-0835 *
OZA V B ET AL: "Synthesis and Evaluation of Anthranilic Acid-Based Transthyretin Amyloid Fibril Inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 1, January 1999 (1999-01-01), pages 1 - 6, XP004154767, ISSN: 0960-894X *
RIDKER PAUL M: "Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?", ANNALS OF INTERNAL MEDICINE, vol. 130, no. 11, 1 June 1999 (1999-06-01), pages 933 - 937, XP002224263, ISSN: 0003-4819 *

Also Published As

Publication number Publication date
WO2002054079A2 (en) 2002-07-11
EP1356283A2 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
DE69632466D1 (en) SOLUTION THE CHAOTROPIC AGENT CONTAINS AND USE OF THIS SOLUTION IN METHODS FOR ISOLATING DNA, RNA AND PROTEINS
HUP0003533A2 (en) Interleukin-18 binding proteins, their preparation and use
CA2257152A1 (en) Methods for detection of rearranged dna
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2001013117A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
DE60041278D1 (en) AMPLIFICATION OF CYP24 AND APPLICATION THEREOF
WO1999047925A3 (en) Methods and compositions for diagnosis of rheumatoid arthritis
WO2000018912A3 (en) Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
ATE384263T1 (en) METHOD FOR DETERMINING BIOLOGICAL AGENTS IN LIVING TARGET CELLS
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia
WO2004051269A3 (en) Ciz1 replication protein
ATE166395T1 (en) OLIGONUCLEOTIDES SPECIFIC FOR C.DIFFICILE
WO2002054079A3 (en) Proteins, genes and their use for diagnosis and treatment of cardiac response
WO2002054080A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular response
ATE283369T1 (en) A TWO-HYBRID SCREENING SYSTEM IN BACTERIA FOR PROTEIN INTERACTION
DE69734199D1 (en) HUMAN NETRIN-1
WO2002046768A3 (en) Proteins, genes and their use for diagnosis and treatment of chronic asthma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001272724

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001272724

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001272724

Country of ref document: EP